(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 January 2010 (07.01.2010)

PCT

(10) International Publication Number
WO 2010/003048 A1

(51) International Patent Classification:
C07D 401/12 (2006.01) *C07D 417/12* (2006.01)
C07D 401/14 (2006.01) *C07D 417/14* (2006.01)
C07D 403/12 (2006.01) *C07D 471/04* (2006.01)
C07D 403/14 (2006.01) *C07D 471/08* (2006.01)
C07D 405/12 (2006.01) *C07D 513/04* (2006.01)
C07D 405/14 (2006.01) *A61K 31/4184* (2006.01)
C07D 413/12 (2006.01) *A61K 31/437* (2006.01)
C07D 413/14 (2006.01)

(21) International Application Number:
PCT/US2009/049498

(22) International Filing Date:
2 July 2009 (02.07.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/133,938 3 July 2008 (03.07.2008) US

(71) Applicant *(for all designated States except US)*: **SIRTRIS PHARMACEUTICALS, INC.** [US/US]; 200 Technology Square, Suite 300, Cambridge, MA 02139 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **VU, Chi, B.** [US/US]; 200 Technology Square, Suite 300, Cambridge, MA 02139 (US). **DISCH, Jeremy, S.** [US/US]; 200 Technology Square, Suite 300, Cambridge, MA 02139 (US). **NG, Pui, Yee** [US/US]; 200 Technology Square, Suite 300, Cambridge, MA 02139 (US). **BLUM, Charles, A.** [US/US]; 200 Technology Square, Suite 300, Cambridge, MA 02139 (US). **PERNI, Robert, B.** [US/US]; 200 Technology Square, Suite 300, Cambridge, MA 02139 (US).

(74) Agents: **SUTTON, Jeffrey, A** et al.; Glaxosmithkline, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*


— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS



(II)

(57) Abstract: Provided herein are sirtuin-modulating compounds of formula (II) The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

WO 2010/003048 A1